資源 » 參考數(shù)據(jù)庫 » 客戶發(fā)表文獻

至今，GenScript的服務及產(chǎn)品已被Cell, Nature, Science, PNAS等1300多家生物醫(yī)藥類雜志引用近萬次，處于行業(yè)領先水平。NIH、哈佛、耶魯、斯坦福、普林斯頓、杜克大學等約400家全球著名機構(gòu)使用GenScript的基因合成、多肽服務、抗體服務和蛋白服務等成功地發(fā)表科研成果，再次證明GenScript 有能力幫助業(yè)內(nèi)科學家Make research easy.

Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor D-1-methyl-tryptophan.

J Hematol Oncol. 2017;

Zhang Xiaolong，Yang Yuanyuan，Zhang Leisheng，Lu Yang，Zhang Qing，F(xiàn)an Dongmei，Zhang Yizhi，Zhang Yanjun，Ye Zhou，Xiong Dongs

Products/Services Used	Details	Operation
Recombinant Proteins	(GenScript, USA) and were used for cell-binding assays and cytotoxicity assays in vitro. In addition	Get A Quote

摘要

Although blinatumomab， a bispecific T cell engaging antibody， exhibits high clinical response rates in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (B-ALL) and B cell non-Hodgkin's lymphoma (B-NHL)， it still has some limitations because of its short half-life. Mesenchymal stromal cells (MSCs) represent an attractive approach for delivery of therapeutic agents to cancer sites owing to their tropism towards tumors， but their immunosuppression capabilities， especially induced by indoleamine 2，3-dioxygenase (IDO)， should also be taken into consideration.